LBB Specialties Partners with Kerry Group to Launch Pharmaceutical Lactose to the Life Sciences Market

April 03, 2025 04:30 AM AEDT | By Cision

Google News:

LBB Specialties Partners with Kerry Group to Launch Pharmaceutical Lactose to the Life Sciences Market — Image source: Kalkine Media

Recent News

Artificial Intelligence ushers bidding review into the intelligent era

XTransfer Wins Regional Best Payments and Collections Solution at The...

Avio Health Launches World's First Functional Medicine LLM for Emagene...

ASX 200 edges higher as materials lift on global optimism

NORWALK, Conn., April 3, 2025 /PRNewswire/ -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution in North America, is pleased to announce a new partnership with Kerry Group, a world leading taste and nutrition partner for the food, beverage, and pharmaceutical markets with innovative, sustainable specialty ingredients for the industry.

Through this collaboration, LBB Specialties will become Kerry's preferred distribution partner in the United States, expanding access to high-quality pharmaceutical lactose ingredients. Kerry's Sheffield™ brand offers a comprehensive range of pharmaceutical lactose excipients in various forms, grades, and particle sizes to provide formulators with optimized solutions for diverse pharmaceutical applications.

"Our partnership with Kerry expands our customers' access to high-quality pharmaceutical lactose ingredients. Kerry's long-standing technical expertise and commitment to product consistency provide formulators with reliable, high-performance solutions tailored to their specific needs. Together, we are redefining quality and innovation in pharmaceutical formulation," said Seth Burns, SVP of Life Sciences at LBB Specialties.

As an industry leader, Kerry provides the industry's extensive portfolio of anhydrous, spray dried and monohydrate grades of lactose. These include Sheffield™ brand N.F. Anhydrous Direct Tableting (DT) lactose, which has been regarded as the gold standard for anhydrous direct compression lactose excipients since its original patent, and Sheffield™ 316 Fast Flo® spray dried lactose. This portfolio will enable formulators to achieve enhanced product consistency, supply chain efficiencies, and greater innovation in drug formulation technologies.

"The agreement will provide customers with even greater access to Kerry's extensive lactose portfolio, ensuring the highest level of availability and customer service," said Joey Glassco, Regional Sales Manager, Pharma Excipients at Kerry.

For more information about Kerry's new line of innovative, sustainable specialty ingredients for the Life Sciences industry, contact LBB Specialties today.

About LBB Specialties LBB Specialties is a leader in North American specialty chemicals and ingredients distribution. It is a diversified supplier serving end markets including care, food & nutrition, industrial specialties, and life sciences. www.LBBSpecialties.com

About Kerry
Kerry is a world leading taste and nutrition partner for the food, beverage, and pharmaceutical markets. We innovate with our customers to create great-tasting products, with improved nutrition and functionality, while ensuring a better impact for the planet. Our leading consumer insights, global RD&A team of 1,100+ food scientists and extensive global footprint enable us to solve our customers' complex challenges with differentiated solutions. At Kerry, we are driven to be our customers' most valued partner, creating a world of sustainable nutrition, and will reach over two billion consumers with sustainable nutrition solutions by 2030. www.kerrygroup.com

Media Contact:
Ahmed Hanafy
[email protected]

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.